menu
    • menu
    [{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"CYT-303","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Naya Biosciences \/ INVO Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ INVO Bioscience"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"NY-303","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Naya Biosciences \/ NAYA Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ NAYA Biosciences"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"AAV-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Naya Biosciences \/ NAYA Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Naya Biosciences \/ NAYA Biosciences"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"AAV-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Naya Biosciences \/ NAYA Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Naya Biosciences \/ NAYA Biosciences"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NY-303","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Naya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Naya Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Naya Biosciences

    Menu

    Naya Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NAYA Biosciences Starts Phase 1/2a Study for GPC3 NK Bispecific Antibody

                            Details : NY-303 is a GPC3-targeting NK engager bispecific antibody, it is being evaluated as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy.

                            Brand Name : NY-303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 24, 2024

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            INVO and NAYA Bioscience Merge, Will Operate As NAYA Biosciences

                            Details : NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy (LHON).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 14, 2024

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            NAYA Biosciences to Acquire Clinical Stage Gene Therapy Program for LHON

                            Details : Through the acquisition, NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONKT105,NY-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : ONK Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimall...

                            Details : The partnership aims to explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody for the treatment of cancer.

                            Brand Name : ONKT105

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : ONKT105,NY-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : ONK Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Naya Biosciences

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Trade...

                            Details : The combined company will work on increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. NAYA Oncology has acquired CYT-303, a clinical-stage bispecific antibody asset for the treatment of Hepatocellu...

                            Brand Name : CYT-303

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 23, 2023

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth